Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

49
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
49
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

49
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
49
Pharmacodynamic Models: Emax Drug–Concentration Effect Model01:18

Pharmacodynamic Models: Emax Drug–Concentration Effect Model

93
The Emax drug-concentration effect model is central to pharmacodynamics in drug discovery and development. This model is predicated on the receptor occupancy theory, which posits that the effect of a drug is directly related to the number of receptors occupied by the drug and the resultant complex formation.The model describes the reversible interaction between a drug (C) and a receptor (R) to form a drug-receptor complex (RC). The kinetics of this interaction are quantified by an equation that...
93
Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect01:28

Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect

69
A drug’s dosage and pharmacokinetic properties determine how quickly it acts, how intense its effects are, and how long it lasts. Higher doses increase drug concentration at receptor sites, producing a hyperbolic curve when pharmacologic response is plotted against drug dose. Converting this scale to a log-linear format results in a sigmoidal curve, better representing dose–response relationships.For drugs following a one-compartment model, the pharmacologic response is directly...
69
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

7.1K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
7.1K
Factors Affecting Dissolution: Particle Size and Effective Surface Area01:23

Factors Affecting Dissolution: Particle Size and Effective Surface Area

1.8K
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
1.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Multimodal immunopharmacologic screens identify drugs rewiring the cancer-immune interface.

bioRxiv : the preprint server for biology·2026
Same author

Preclinical models of hepatosplenic γδ T-cell lymphoma with an activating STAT5B mutation display sensitivity to JAK inhibitor upadacitinib.

HemaSphere·2026
Same author

Prognostic biomarker discovery in pancreatic cancer through hybrid ensemble feature selection and multi-omics data.

BioData mining·2026
Same author

Discovery of predictive biomarkers for cancer therapy through computational approaches.

Nature reviews. Clinical oncology·2026
Same author

From library to landscape: integrative annotation workflows for compound libraries in drug repurposing.

Database : the journal of biological databases and curation·2025
Same author

Improved analysis of in vivo drug combination experiments with a comprehensive statistical framework and web-tool.

Nature communications·2025

相关实验视频

Updated: Mar 7, 2026

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

1.4K

扩大药物组合表面预测的规模.

Riikka Huusari1, Tianduanyi Wang1,2, Sandor Szedmak1

  • 1Department of Computer Science, Aalto University, Otakaari 1B, FI-00076 Espoo, Finland.

Briefings in bioinformatics
|March 13, 2025
PubMed
概括

机器学习模型更有效地预测药物组合反应,通过预测整个剂量-反应表面,而不仅仅是协同效应得分. 这种方法通过优先考虑有效的药物组合来增强癌症治疗策略.

关键词:
药物组合的预测和预测.药物相互作用的表面.核心方法 核心方法结构化的输出预测预测.

更多相关视频

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.7K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.8K

相关实验视频

Last Updated: Mar 7, 2026

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

1.4K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.7K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.8K

科学领域:

  • 计算生物学是一种计算生物学.
  • 药理学 药理学是指药理学的学科.
  • 机器学习 机器学习

背景情况:

  • 药物组合对于治疗高级癌症等复杂疾病至关重要.
  • 与单一治疗相比,协同药物组合提供了更高的疗效和更低的毒性.
  • 目前的药物组合查是昂贵和耗时的,需要高效的预测模型.

研究的目的:

  • 开发和评估一个改进的机器学习模型 (comboKR 2.0) 用于预测完整的药物组合剂量反应表面.
  • 通过采用功能输出方法来解决现有的标量值预测方法的局限性.
  • 加强对实验验证的潜在协同药物组合的优先考虑.

主要方法:

  • 实现了 comboKR 方法的扩展配方,结合了响应表面的新型建模选择.
  • 开发了一种预测梯度下降方法,以解决功能输出预测中的前图像问题.
  • 利用了输入-输出内核回归和响应表面的功能建模.

主要成果:

  • comboKR 2.0在三个现实数据集中展示了强大的预测性能,包括使用未见药物或细胞系的场景.
  • 功能输出预测方法的表现优于传统的协同效应得分预测方法.
  • 预计的梯度下降方法有效地解决了图像前的问题.

结论:

  • 药物组合剂量反应表面的功能输出预测提供了一个比协同得分更相关和更强大的方法.
  • 增强的comboKR 2.0模型为癌症研究中优先考虑药物组合提供了可靠的工具.
  • 这种方法可以加速发现复杂疾病的有效组合疗法.